In particular, patients with metastatic NSCLC harboring mutations in KEAP1, NFE2L2, or CUL3 showed significantly shorter time to treatment failure and OS following first-line platinum doublet chemotherapy, compared to matched controls [71]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.